Anogen-Yes Biotech

06/17/2026

The Alzheimer's treatment landscape is evolving rapidly, with researchers expanding beyond traditional symptom management toward therapies that may slow disease progression.

Recent milestones include the FDA approvals of Leqembi® (lecanemab) and Kisunla™ (donanemab), the first disease-modifying treatments designed to target amyloid-beta pathology in Alzheimer's disease.

Looking ahead, scientists are actively exploring:

🔹 Next-generation amyloid-clearing therapies
🔹 Novel therapeutic targets beyond amyloid, including neuroinflammation and neuroprotection
🔹 Oral treatment options to improve accessibility and patient convenience
🔹 Non-invasive approaches such as brain stimulation and focused ultrasound
🔹 Lifestyle interventions that may help reduce Alzheimer's risk

With nearly 200 clinical trials evaluating more than 150 investigational therapies, the future of Alzheimer's research is becoming increasingly diverse and promising. As our understanding of the disease continues to grow, innovative therapeutic strategies may help transform the way Alzheimer's is treated in the years ahead.

Source: BrightFocus Foundation
https://www.brightfocus.org/resource/expanding-the-alzheimers-treatment-landscape-a-2026-forecast/

Learn about the treatments landscape for Alzheimer’s in 2026 and beyond.

06/10/2026

Tiziana Life Sciences recently announced positive updated clinical data for its lead candidate, intranasal foralumab, in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS).

Key highlights from the ongoing Expanded Access Program include:

✔ Disease improvement or stabilization observed in all 14 treated patients within 6 months
✔ Favorable trends in disability stabilization (EDSS)
✔ Clinically meaningful improvements in fatigue scores (MFIS)
✔ Continued demonstration of a favorable safety and tolerability profile

Foralumab is a fully human anti-CD3 monoclonal antibody designed to stimulate regulatory T cells through intranasal administration, representing a novel approach to modulating neuroinflammation without broad systemic immunosuppression.

With limited treatment options currently available for na-SPMS, these findings further support the potential of targeted immunomodulatory therapies in neurodegenerative and neuroinflammatory diseases.

Read more: https://www.tizianalifesciences.com/tiziana-announces-new-positive-clinical-data-for-intranasal-foralumab-in-non-active-secondary-progressive-multiple-sclerosis/

Patients showed encouraging trends in stabilization of disability as measured by the Expanded Disability Status Scale (EDSS) and meaningful improvements in fatigue as measured by the Modified Fatigue Impact Scale (MFIS).

06/03/2026

🔬 Anti-IL-8 antibodies continue to emerge as promising therapeutic candidates across oncology and inflammatory diseases.

In oncology, IL-8 blockade has been investigated as a strategy to overcome tumor-associated immune suppression and enhance responses to checkpoint inhibitors. Anti-IL-8 antibodies such as BMS-986253 have demonstrated the ability to modulate the tumor microenvironment and support antitumor immune activity.

Beyond cancer, the long-acting anti-IL-8 antibody AMY109 is advancing in endometriosis research. Preclinical and early clinical studies suggest that targeting IL-8 may reduce inflammation, fibrosis, and lesion development while maintaining a favorable safety profile.

As understanding of IL-8 biology expands, anti-IL-8 therapeutics may offer new opportunities for treating both cancer and chronic inflammatory diseases.

Reference:
BMS-986253 / HuMax-IL8 Phase I trial (PubMed), https://pubmed.ncbi.nlm.nih.gov/31488216/
Melanoma immunotherapy studies ESMO Report https://dailyreporter.esmo.org/esmo-immuno-oncology-congress-2022/other-news/preliminary-activity-is-reported-with-an-anti-il-8-monoclonal-antibody-plus-nivolumab-in-melanoma?utm_source=chatgpt.com

Combination therapy with BMS-986253 shows promise in patients progressing on checkpoint inhibitors

05/27/2026

🧠 New research highlights the potential role of immunotherapy in healthy brain aging.

Tiziana Life Sciences recently reported preclinical data showing that nasal anti-CD3 therapy improved cognition associated with aging, supporting growing interest in targeting neuroinflammation for cognitive health.

Key highlights:

✔ Improved cognition observed in aging models
✔ Non-invasive nasal anti-CD3 immunotherapy approach
✔ Potential applications in neuroinflammation and age-related cognitive decline

These findings continue to support the emerging connection between immune modulation and brain health research.

🔗 Read more: https://www.globenewswire.com/news-release/2026/04/01/3266479/0/en/tiziana-announces-data-showing-nasal-anti-cd3-improves-cognition-associated-with-aging.html

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate,...

05/20/2026

Tiziana Life Sciences recently reported reduced brain inflammation in patients with non-active secondary progressive multiple sclerosis (SPMS) treated with intranasal foralumab, an investigational anti-CD3 monoclonal antibody therapy.

Key findings include:
✔ Reduction of microglial activation observed through PET imaging
✔ Potential non-invasive immunomodulatory approach for neuroinflammatory diseases
✔ Continued progress in multiple sclerosis and CNS inflammation research

These findings highlight the growing interest in targeted immune therapies for neurological disorders and the important role of inflammation in disease progression.

🔗 Read more: https://ir.tizianalifesciences.com/news-releases/news-release-details/tiziana-reports-reduced-brain-inflammation-multiple-system

05/13/2026

🧠 Vitamin D May Play a Bigger Role in Brain Health Than We Thought

Recent research continues to highlight the connection between vitamin D deficiency and increased risk of cognitive decline, dementia, and Alzheimer’s disease.

Key findings include:

✔ Low vitamin D levels linked to higher dementia risk
✔ Severe deficiency associated with significantly increased Alzheimer’s risk
✔ Vitamin D may help support memory, mood, immunity, and cognitive function
✔ Emerging studies suggest vitamin D could help reduce beta-amyloid accumulation in the brain

With vitamin D deficiency remaining common worldwide, maintaining optimal levels may be an important factor in supporting long-term brain health.

🔗 Read more: https://www.amenclinics.com/blog/the-shocking-connection-between-vitamin-d-and-dementia-risk/

If we don’t look at the brain, we are unnecessarily flying blind. Learn how traditional psychiatry missed the root cause of Jason’s mental illness.

05/06/2026

Anti-IL-17A Therapies Continue to Expand Across Immunology & Inflammatory Diseases 🔬

Recent 2026 developments highlight the growing impact of IL-17A-targeting antibodies in both autoimmune diseases and oncology research:

✔ FDA approval of Cosentyx® (secukinumab) for pediatric hidradenitis suppurativa patients aged 12+
✔ China NMPA acceptance of Akeso’s gumokimab (AK111) NDA for ankylosing spondylitis
✔ Ongoing research into combining IL-17A blockade with anti-PD-1/PD-L1 immunotherapy to address cancer treatment resistance
✔ Continued advancement of dual IL-17A/F inhibitors such as bimekizumab
As IL-17A pathways gain increasing attention across dermatology, rheumatology, and cancer immunotherapy, demand for reliable cytokine and immunology research tools continues to grow.

🔗 Read more:
https://www.novartis.com/us-en/news/media-releases/novartis-cosentyx-receives-fda-approval-pediatric-patients-aged-12-moderate-severe-hidradenitis-suppurativa?utm_source=chatgpt.com

Cosentyx is the only IL‑17A inhibitor approved for this population, and the first differentiated mechanism in nearly a decade1-3 HS often emerges around puberty, underscoring importance of early diagnosis and intervention with biologics to help reduce long-term disease burden4-6 Approval marks fou...

04/29/2026

The latest Antibodies to Watch 2026 report highlights the rapid expansion of antibody-based therapeutics:

✔ 19 new antibody approvals in 2025
✔ 200+ molecules in late-stage development
✔ Increasing adoption of advanced formats such as ADCs and bispecific antibodies

One of the most notable trends is the global shift in innovation. Over 50% of newly approved antibodies in 2025 originated from China, reflecting a rapidly evolving and competitive landscape.

With an average development timeline of ~6 years—and even faster in some regions—the pace of innovation in antibody therapeutics continues to accelerate.

As the field advances, reliable tools for antibody characterization, biomarker analysis, and immunoassay development remain essential to support this growth.

Read the full article here: https://www.tandfonline.com/doi/full/10.1080/19420862.2026.2614669

The Antibodies to Watch article series provides annual updates on commercial late-stage clinical development, regulatory review, and marketing approvals of antibody therapeutics. Since the first ar...

04/22/2026

A recent publication from Tiziana Life Sciences highlights the potential of intranasal anti-CD3 therapy (foralumab) in modulating immune responses.

This innovative approach:

✔ Targets immune balance rather than broad suppression

✔ Utilizes a non-invasive intranasal delivery method

✔ Shows promise in addressing neuroinflammatory and autoimmune conditions

As research continues, therapies like this may open new pathways for treating complex CNS disorders, including Alzheimer’s and multiple sclerosis.

At Anogen, we support advancing immunology research with reliable tools for cytokine and immune profiling.

🔗 Read more: https://finance.yahoo.com/sectors/healthcare/articles/tiziana-life-sciences-announces-publication-110000819.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAJKA8oHHKhd7J78oW3jheEu-Y2RkdmpjazN5qJPYuUK5pVrwTHjM17f0eMBx2jojlLCOP_n8mRfbi4Rmlc6HSlOtfl9yOo0n2NxUNXrWrK3ccwDN2nqHiORyDgs8yJ3qflWnNdhvERieMNBcNkVU97WtUGbzUql2RTs5dBVAZPfy

-T

Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company’s lead candidate, intranasal foralumab, for Long COVID associated “brain fog”.BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”)...

04/22/2026

A recent publication from Tiziana Life Sciences highlights the potential of intranasal anti-CD3 therapy (foralumab) in modulating immune responses.

This innovative approach:

✔ Targets immune balance rather than broad suppression

✔ Utilizes a non-invasive intranasal delivery method

✔ Shows promise in addressing neuroinflammatory and autoimmune conditions

As research continues, therapies like this may open new pathways for treating complex CNS disorders, including Alzheimer’s and multiple sclerosis.

At Anogen, we support advancing immunology research with reliable tools for cytokine and immune profiling.

🔗 Read more: https://finance.yahoo.com/sectors/healthcare/articles/tiziana-life-sciences-announces-publication-110000819.html?guccounter=1&guce_referrer=aHR0cHM6Ly93d3cuZ29vZ2xlLmNvbS8&guce_referrer_sig=AQAAAJKA8oHHKhd7J78oW3jheEu-Y2RkdmpjazN5qJPYuUK5pVrwTHjM17f0eMBx2jojlLCOP_n8mRfbi4Rmlc6HSlOtfl9yOo0n2NxUNXrWrK3ccwDN2nqHiORyDgs8yJ3qflWnNdhvERieMNBcNkVU97WtUGbzUql2RTs5dBVAZPfy

-T

Data from independent academic collaborators published on bioRxiv support the therapeutic potential of the Company’s lead candidate, intranasal foralumab, for Long COVID associated “brain fog”.BOSTON, April 16, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”)...